Non-Small Cell Lung Cancer Video Perspectives

In July 2021, Balazs Halmos, MD, chief of thoracic/head and neck oncology at Montefiore Medical Center and professor of medicine at Albert Einstein College of Medicine, spoke with Healio about the importance of genetic testing, novel therapeutic agents and concerns about resistance in non-small cell lung cancer.

In this video, Halmos discussed:

• The “critical” role that genomic biomarker testing plays in determining the optimal treatment for patients with NSCLC;
• Challenges that clinicians face when treating metastatic NSCLC, including the need for appropriate diagnostic testing and staging to select not only first-line treatment, but second- and third-line therapies as well;
• The emergence and successful FDA approval of multiple generations of ALK inhibitors;
• Concerns about resistance to targeted therapies in metastatic NSCLC and research showing the potential of two new classes of agents in overcoming resistance;
• The “very extensive” pipeline of drugs for management of NSCLC, including various targeted therapies and immunotherapies; and
• Exciting areas of research in NSCLC, such as the development of KRAS G12C-targeting agents.